New Delhi: China has approved the world’s first inhaled version of a Covid-19 vaccine has been approved made by CanSino Biologics Inc. China’s National Medical Products Administration (NMP) gave nod to CanSino Ad5-nCoV for emergency use as a booster vaccine, news agency Bloomberg reported.
World’s First Inhaled Covid-19 Vaccine
CanSino's vaccine named "Convidecia Air" is the inhaled version of the Tianjin-based company's adenoviral vector vaccine, Convidecia. China Global Television Network quoting CanSino said the inhaling vaccine "provides a non-invasive option" and the new vaccine can establish immunity against Covid-19 after "just one breath."
The company in a statement said the Phase III trial results published in the medical journal The Lancet indicate that the new vaccine can induce strong humoral, cellular and mucosal immunity to achieve triple protection and effectively contain the infection and spread of the virus.
The inhaled version of the vaccine can be self-administered as well which makes it suitable for vaccine-hesitant people, as per the company.
ALSO ON ABP LIVE: COVID-19 Cases Continue To Decline As India Logs 6,809 Fresh Infections, 26 Fatalities In 24 Hours (abplive.com)
The inhaled version uses a modified cold-causing virus to expose the immune system to the coronavirus and was found to be similar to those developed by AstraZeneca Plc and Johnson & Johnson, as per the Bloomberg report.
At present, the company has achieved steady production of various innovative vaccines and managed to establish a global supply chain. However, the company is not clear when its vaccine would access the market since additional administrative approvals are still needed, while sales would depend on the Covid-19 situation at home and abroad, as well as China's vaccination rate, according to Reuters.
READ | How Safe Is Mercedes GLC Involved In Cyrus Mistry Accident? Know What Is Its Crash Test Rating